| Autor: |
Nakamura de Vasconcelos, Sandra S, Caleffi-Ferracioli, Katiany R, Hegeto, Laíse A, Baldin, Vanessa P, Nakamura, Celso V, Stefanello, Talitha F, Freitas Gauze, Gisele de, Yamazaki, Diego AS, Scodro, Regiane BL, Siqueira, Vera LD, Cardoso, Rosilene F |
| Zdroj: |
Future Microbiology; June 2018, Vol. 13 Issue: 8 p877-888, 12p |
| Abstrakt: |
Aim:Evaluating carvacrol, derivatives and carvacrol plus anti-TB (anti-tuberculous) drug combination activities in Mycobacterium tuberculosisas well as carvacrol cytotoxicity, efflux pump inhibitor activity and morphological changes in M. tuberculosisH37Rv. Methods:Carvacrol (CAR) and derivatives’ activities were determined by resazurin microtiter assay and drug interaction by resazurin drug combination microtiter. Carvacrol cytotoxicity in VERO cells and efflux pumps inhibitor activity by ethidium bromide assay were determined and scanning electron microscopy performed. Results:Carvacrol MIC ranged from 19 to 156 μg/ml and carvacrol plus rifampicin combination showed synergistic effect in clinical isolates. No anti-M. tuberculosisactivity improvement was observed with carvacrol derivatives. Carvacrol showed to be selective for M. tuberculosis, to have efflux pumps activity and to induce rough bacillary and agglomerates. Conclusion:Carvacrol shows good anti-M. tuberculosisactivity and synergism with rifampicin. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
